Literature DB >> 9716380

Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene.

N Yanaka1, J Kotera, A Ohtsuka, H Akatsuka, Y Imai, H Michibata, K Fujishige, E Kawai, S Takebayashi, K Okumura, K Omori.   

Abstract

cGMP-binding, cGMP-specific phosphodiesterase which is encoded by the PDE5A gene plays important roles in cardiovascular system, and is a significant target molecule of therapeutic agents. However, little is known about molecular characteristics of the human PDE5A gene. The 4.4-kb cDNA encoding human PDE5A was isolated from lung and placenta cDNA libraries. The deduced amino acid sequence analysis demonstrated that N-terminal amino acid sequence is dissimilar to that of rat PDE5A [Kotera, J., Yanaka, N., Fujishige, K., Imai, Y., Akatsuka, H., Ishizuka, T., Kawashima, K. & Omori, K. (1997) Eur. J. Biochem. 249, 434-442]. Human PDE5A mRNA is produced in high amounts in various tissues such as pancreas, skeletal muscle, placenta, heart, thyroid, adrenal cortex, testis, small intestine and stomach. In addition, the megakaryocyte-like cell line Dami cells and two types of human vascular smooth muscle cells also produce the mRNA. Over 100-kb chromosomal DNA corresponding to the human PDE5A gene was isolated and analyzed. The human PDE5A gene was revealed to contain 21 exons. Comparison of genomic organization with the rod photoreceptor phosphodiesterase beta-subunit gene (PDE6B), which is another kind of cGMP-specific phosphodiesterase, has shown that the PDE5A and PDE6B genes are very similar in their relative exon intron organization. In particular, the evolutionary relatedness of these genes was suggested in the catalytic domain. Furthermore, chromosomal location of the PDE5A gene was defined as being chromosome 4q26 by fluorescent in situ hybridization analysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716380     DOI: 10.1046/j.1432-1327.1998.2550391.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  21 in total

Review 1.  The emerging role for type 5 phosphodiesterase inhibition in heart failure.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2006-09

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

3.  Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis.

Authors:  Angela Scipioni; Stefania Stefanini; Rocco Santone; Mauro Giorgi
Journal:  Histochem Cell Biol       Date:  2005-11-03       Impact factor: 4.304

4.  Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.

Authors:  Dongsoo Kim; Toru Aizawa; Heng Wei; Xinchun Pi; Sergei D Rybalkin; Bradford C Berk; Chen Yan
Journal:  J Mol Cell Cardiol       Date:  2004-12-08       Impact factor: 5.000

5.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

6.  Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart.

Authors:  Peter Dazert; Konrad Meissner; Silke Vogelgesang; Björn Heydrich; Lothar Eckel; Michael Böhm; Rolf Warzok; Reinhold Kerb; Ulrich Brinkmann; Elke Schaeffeler; Matthias Schwab; Ingolf Cascorbi; Gabriele Jedlitschky; Heyo K Kroemer
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

Review 7.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis.

Authors:  C Moro; E Klimcakova; M Lafontan; M Berlan; J Galitzky
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

Review 9.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.